|
PTC is currently enrolling a Phase 2 clinical study of PTC299 in neurofibromatosis type 2. Participants take PTC299 by mouth twice per day. Each patient receives the drug continuously for up to 48 weeks. Magnetic resonance imaging (MRI) scans, hearing tests, and blood tests are conducted before the first dose and every 8 weeks during the course of treatment. More information about the trial can be found at
www.clinicaltrials.gov
Neurofibromatosis Type 2 Clinical Trial Overview >
Neurofibromatosis Type 2 Trial FAQs >
PTC is currently enrolling a Phase 1/2 clinical study of PTC299 in HIV-related Kaposi’s sarcoma (KS). Participants take PTC299 by mouth twice per day. Each participant takes the drug in 28-day treatment cycles. Cycles of treatment can continue for up to 48 weeks as long as PTC299 appears to be safely offering tumor control. Participants will continue taking their usual treatments for HIV infection. More information about the trial can be found at www.clinicaltrials.gov
Kaposi's Sarcoma Clinical Trial Overview >
Kaposi's Sarcoma Clinical Trial Sites >
Kaposi's Sarcoma Clinical Trial FAQs >
PTC is currently enrolling a Phase 1b/2 clinical study of PTC299 in metastatic breast cancer is ongoing at New York University Medical Center. Patients participating in this study take PTC299 by mouth twice a day. Each patient receives the drug in 6-week treatment cycles. Cycles of treatment are repeated for as long as the patient wishes to participate and is potentially benefiting from the drug in the course of the study. This study is testing different doses of PTC299 to further evaluate the activity and safety of the drug. Additionally, the study is monitoring whether PTC299 lowers levels of VEGF in the blood and whether the drug reduces the flow of blood to the tumors and, in turn, decreases tumor size. More information about the trial can be found at www.clinicaltrials.gov
Metastatic Breast Cancer Clinical Trial Overview >
Metastatic Breast Cancer Clinical Trial Sites >
PTC is currently enrolling a Phase 1b clinical study of PTC299 in advanced solid tumors. Working together with doctors at Memorial Sloan-Kettering Cancer Center in New York City, PTC Therapeutics is now conducting a three stage study. In Stage 1, up to 18 patients will receive increasingly higher doses of PTC299 in a repeated on-off pattern (4 weeks on drug and 2 weeks off drug) to assess the drug’s safety. In Stage 2, a second group of up to 12 patients will receive PTC299 every day. In Stage 3, a third group of up to 12 patients will receive PTC299 together with the chemotherapy medication, docetaxel (Taxotere®). More information about the trial can be found at www.clinicaltrials.gov
Additional information about these PTC299 clinical trials can be found at www.clinicaltrials.gov or by contacting Patient and Professional Advocacy at (866) 282-5873, (908) 912-9256 or PatientInfo@ptcbio.com
Advanced Solid Tumors Clinical Trial Overview >
|